Jasper Therapeutics (Nasdaq:JSPR) - Aandelenkoers, Nieuws & Analyse

JSPR Overzicht aandelen

Jasper Therapeutics, Inc., een biotechnologiebedrijf in een klinische fase, ontwikkelt therapeutische middelen voor hematopoëtische stamceltransplantatie en gentherapieën. Meer informatie

JSPR fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 72.57% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst zal naar verwachting de komende drie jaar met gemiddeld 16.4% per jaar dalen.

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

+ 1 meer risico

Jasper Therapeutics, Inc. Concurrenten

C4 Therapeutics

NasdaqGS:CCCC

US$285.9m

uniQure

NasdaqGS:QURE

US$277.8m

COMPASS Pathways

NasdaqGS:CMPS

US$318.8m

Sage Therapeutics

NasdaqGM:SAGE

US$300.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Jasper Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$21.84
52 Week Hoogtepunt	US$31.01
52 Week Laag	US$4.00
Bèta	2.2
11 maand verandering	8.76%
3 maanden verandering	13.22%
1 Jaar Verandering	250.79%
33 jaar verandering	-71.96%
5 jaar verandering	n/a
Verandering sinds IPO	-77.76%

Recent nieuws en updates

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 18

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30

Recent updates

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 18

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Nov 28

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Nov 23

Rendement voor aandeelhouders

	JSPR	US Biotechs	US Markt
7D	-1.2%	-3.7%	0.3%
1Y	250.8%	15.2%	31.1%

Rendement versus industrie: JSPR overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 15.2 % opleverde.

Rendement versus markt: JSPR overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.1 %.

Prijsvolatiliteit

Is JSPR's price volatile compared to industry and market?
JSPR volatility
JSPR Average Weekly Movement	11.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van JSPR is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van JSPR is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	45	Ron Martell	www.jaspertherapeutics.com/

Jasper Therapeutics, Inc., een biotechnologiebedrijf in een klinische fase, ontwikkelt therapeutische middelen voor hematopoëtische stamceltransplantatie en gentherapieën. De belangrijkste productkandidaat van het bedrijf is briquilimab, dat in klinische ontwikkeling is als een nieuw therapeutisch antilichaam dat hematopoëtische stamcellen uit het beenmerg verwijdert bij patiënten voorafgaand aan het ondergaan van allogene stamceltherapie of stamcelgentherapie. Het bedrijf richt zich op de ontwikkeling en commercialisering van therapeutische middelen voor ziekten zoals chronische spontane urticaria, myelodysplastisch syndroom met een laag tot gemiddeld risico en conditioneringsschema's voor stamceltransplantatie.

Jasper Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Jasper Therapeutics zich tot de beurswaarde?
JSPR fundamentele statistieken
Marktkapitalisatie	US$314.73m
Inkomsten(TTM)	-US$63.53m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-5.2x

Koers/Winstverhouding

Is JSPR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
JSPR resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$63.53m
Inkomsten	-US$63.53m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-4.23
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde JSPR op de lange termijn?

Bekijk historische prestaties en vergelijking

JSPR Overzicht aandelen

Beloningen

Risicoanalyse

Jasper Therapeutics, Inc. Concurrenten

NasdaqGS:CCCC

US$285.9m

NasdaqGS:QURE

US$277.8m

NasdaqGS:CMPS

US$318.8m

NasdaqGM:SAGE

US$300.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Jasper Therapeutics, Inc. Reports Positive Data from Spotlight Study of Briquilimab in Chronic Inducible Urticaria

New minor risk - Share price stability

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target increased by 7.7% to US$69.13

Jasper Therapeutics, Inc. Announces Board Changes

Recent updates

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Jasper Therapeutics, Inc. Reports Positive Data from Spotlight Study of Briquilimab in Chronic Inducible Urticaria

New minor risk - Share price stability

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target increased by 7.7% to US$69.13

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

Asper Therapeutics, Inc Announces the Expansion of its Mast Cell Development Portfolio with Phase 1b/2a Study Evaluating Briquilimab in Asthma Patients

Jasper Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia

Jasper Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50.505 million.

New major risk - Share price stability

Jasper Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.505 million.

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Price target decreased by 11% to US$61.25

Jasper Therapeutics Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of Common Stock for Continued Listing on the Nasdaq Capital Market

Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023

Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

Less than half of directors are independent

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

Jasper Therapeutics, Inc. Announces Board Changes

Jasper Therapeutics Receives Written Notice from Nasdaq Regarding Minimum $1.00 Per Share Requirement

Jasper Therapeutics, Inc. Announces Chief Financial Officer Changes

Price target increased by 9.8% to US$6.88

New major risk - Revenue and earnings growth

Jasper Therapeutics Strengthens Management Team with Key Appointments

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jasper Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome

Jasper Therapeutics, Inc. Appoints Scott Brun to Its Board of Directors

CFO, COO & Corporate Secretary notifies of intention to sell stock

Jasper Therapeutics, Inc. Announces Appointment of Edwin J. Tucker as Chief Medical Officer

Jasper Therapeutics, Inc. Announces Appointment of Stephen J. Galli to Scientific Advisory Board

Jasper Therapeutics, Inc. Appoints Vishal Kapoor as Class I Director

Price target increased by 11% to US$5.97

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Price target decreased by 9.0% to US$7.10

Jasper Therapeutics, Inc. Announces New Positive Briquilimab Data to Be Presented at the 2023 Tandem Meetings

Jasper Therapeutics, Inc. Announces Development Prioritization of Briquilimab in Chronic Diseases

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as A Conditioning Treatment for Patients Prior to Receiving A Stem Cell Transplant

Jasper Therapeutics, Inc. Announces Positive Clinical Data from A Phase I/Ii Trial of Briquilimab as A Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

Price target decreased to US$7.80

High number of new directors

Price target decreased to US$12.00

Jasper Therapeutics Receives Written Notice from Nasdaq

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, A Novel Monoclonal Antibody Targeting CD117, in the Treatment of Patients with Severe Combined Immunodeficiency (SCID) Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Price target decreased to US$12.25

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Non-Executive Chairperson of the Board notifies of intention to sell stock

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

Jasper Therapeutics, Inc. Announces Development of Novel Curative Therapies Based on the Biology of the Hematopoietic Stem Cell

Jasper Therapeutics, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

Jasper Therapeutics, Inc. Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

High number of new directors

Jasper Therapeutics, Inc. Announces Executive Changes